The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was ...

6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema ... that treats eye diseases, so patients don’t need frequent injections.

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections. The FDA has ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to US retina ...

Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment ... the most common ocular side effects included conjunctival hemorrhage, eye pain ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

Susvimo is now available to U.S. retina specialists and their patients with DME. "Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a ...

4-6 Susvimo is now available to US retina specialists and their patients with DME. “Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a ...